These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy. Homick JL; Kohl RL; Reschke MF; Degioanni J; Cintron-Trevino NM Aviat Space Environ Med; 1983 Nov; 54(11):994-1000. PubMed ID: 6651736 [TBL] [Abstract][Full Text] [Related]
4. Transdermal scopolamine for motion sickness. Med Lett Drugs Ther; 1981 Oct; 23(21):89-90. PubMed ID: 7027000 [No Abstract] [Full Text] [Related]
5. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects. Shupak A; Gordon CR; Spitzer O; Mendelowitz N; Melamed Y Pharmatherapeutica; 1989; 5(6):365-70. PubMed ID: 2594820 [TBL] [Abstract][Full Text] [Related]
6. Transderm scopolamine efficacy related to time of application prior to the onset of motion. Levy GD; Rapaport MH Aviat Space Environ Med; 1985 Jun; 56(6):591-3. PubMed ID: 4015572 [TBL] [Abstract][Full Text] [Related]
7. Transdermal scopolamine delivery system (TRANSDERM-V) and acute angle-closure glaucoma. Hamill MB; Suelflow JA; Smith JA Ann Ophthalmol; 1983 Nov; 15(11):1011-2. PubMed ID: 6651138 [TBL] [Abstract][Full Text] [Related]
11. Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo--a comparative study at sea. Noy S; Shapira S; Zilbiger A; Ribak J Aviat Space Environ Med; 1984 Nov; 55(11):1051-4. PubMed ID: 6508687 [TBL] [Abstract][Full Text] [Related]
12. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. Nachum Z; Shupak A; Gordon CR Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539 [TBL] [Abstract][Full Text] [Related]
13. A case report: unilateral cycloplegia resulting from careless use of Transderm-V. Roper DL; Hale LL Aviat Space Environ Med; 1982 Nov; 53(11):1129-30. PubMed ID: 7150175 [No Abstract] [Full Text] [Related]
14. Cycloplegia from transdermal scopolamine. Vincent FM; Vincent T South Med J; 1985 Dec; 78(12):1527-8. PubMed ID: 4071194 [No Abstract] [Full Text] [Related]
15. Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning. Parrott AC Aviat Space Environ Med; 1989 Jan; 60(1):1-9. PubMed ID: 2647072 [TBL] [Abstract][Full Text] [Related]
17. Influence of transdermal scopolamine on motion sickness during 7 days' exposure to heavy seas. van Marion WF; Bongaerts MC; Christiaanse JC; Hofkamp HG; van Ouwerkerk W Clin Pharmacol Ther; 1985 Sep; 38(3):301-5. PubMed ID: 4028625 [TBL] [Abstract][Full Text] [Related]
18. Withdrawal symptoms after discontinuation of transdermal scopolamine therapy: treatment with meclizine. Patel PN; Ezzo DC Am J Health Syst Pharm; 2009 Nov; 66(22):2024-6. PubMed ID: 19890085 [TBL] [Abstract][Full Text] [Related]
19. Transdermal scopolamine intoxication in a child. Klein BL; Ashenburg CA; Reed MD Pediatr Emerg Care; 1985 Dec; 1(4):208-9. PubMed ID: 3842169 [No Abstract] [Full Text] [Related]
20. Head injury and anisocoria on a cruise ship. Dahl E Int Marit Health; 2016; 67(3):159-60. PubMed ID: 27681215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]